Neurocrine Biosciences EV/EBIT NBIX

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2012.

Today, Oct 23, 2026: 18.2×
8-year median: 34.4×
Against its 8-year history: 3rd; percentile: 0 is its lowest day, 100 its highest
8-year range: 14.4× to 193×
Peer median: 24.0×

Neurocrine Biosciences' EV/EBIT is 18.2× as of Oct 23, 2026.

That is below its 8-year median of 34.4×, lower than on 97% of days in the last 8 years.

Over that time it ranged from 14.4× in Apr 2025 to 193× in Apr 2019.

The median for 10 biotech stocks of a similar size is 24.0×.

EV/EBIT over time

median 34.4×

The dashed line is the 8-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	18.2×	17.4×	24.3×
2025	25.0×	14.4×	28.0×
2024	22.2×	18.4×	40.9×
2023	37.7×	30.2×	56.0×
2022	54.3×	32.3×	67.3×
2021	36.9×	25.5×	40.5×
2020	25.2×	23.3×	62.3×
2019	60.0×	60.0×	193×
2018	105×	105×	164×
2017	n/m a value too high to mean anything
2016	n/m a value too high to mean anything
2015	n/m a value too high to mean anything
2014	n/m a value too high to mean anything
2013	428×	378×	439×
2012	11.7×	8.3×	14.1×

Against its peers

Companies in Biotechnology nearest Neurocrine Biosciences' size, closest first, today.

Company	EV/EBIT
NBIXNeurocrine Biosciences	18.2×
HALOHalozyme Therapeutics	17.4×
EXELExelixis	15.4×
TECHBIO-TECHNE	44.9×
RGENRepligen	160×
KRYSKrystal Biotech	42.4×
INCYIncyte	10.1×
UTHRUnited Therapeutics	16.1×
ALNYAlnylam Pharmaceuticals	27.9×
ONCBeOne Medicines	42.2×
REGNRegeneron Pharmaceuticals	20.0×
Peer median	24.0×

Where Neurocrine Biosciences ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Neurocrine Biosciences

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.